Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences' stock (ENSC) has experienced significant volatility and decline in the past six months. As of March 18, 2026, the share price was $0.63, an 83.25% decline from $3.77 on March 19, 2025, and a 70% loss since November 30, 2025. Key events include continued financial losses and high cash burn, the initiation of a Phase 3 trial for PF614, FDA Breakthrough Therapy designation for PF614-MPAR, a review of strategic alternatives, a patent allowance in Brazil, a first peer-reviewed clinical publication, and the release of fourth quarter and full year 2025 financial results.

There is no explicit information available indicating demand seasonality for Ensysce Biosciences, Inc.'s products or services. Demand for its products, once commercialized, would typically be driven by medical necessity and prescription rates rather than seasonal patterns.

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing innovative solutions for severe pain relief while addressing opioid misuse, abuse, and overdose. The company operates in the Healthcare sector and Pharmaceutical Preparations industry. Ensysce's core business revolves around the Trypsin Activated Abuse Protection (TAAP™) platform, designed to create abuse-resistant prodrugs, and the Multi-Pill Abuse Resistant (MPAR®) platform, an overdose protection technology. Key products and pipeline candidates include PF614, a TAAP™ extended-release oxycodone; PF614-MPAR, which combines PF614 with MPAR® technology and has received FDA Breakthrough Therapy designation; PF8026, a novel immediate-release amphetamine prodrug for ADHD; PF9001, a program advancing for opioid use disorder (OUD); and Nafamostat, an ingredient in the company's overdose protection combination products, also being developed for treating infection and pulmonary lung diseases.

Ensysce Biosciences, Inc. has its corporate office in La Jolla, California, United States. The company is expanding its global intellectual property protection for its next-generation analgesics, with allowances in North America, the EU, and South America. In January 2026, the Brazilian Patent Office issued a Notice of Allowance for a patent covering additional opioid families utilizing the company's TAAP™ and MPAR® technologies.

Ensysce Biosciences' brand reputation is shaped by its mission to address the opioid crisis through safer prescription drugs. Positive events include a peer-reviewed clinical publication demonstrating oral overdose protection with MPAR® technology, FDA Breakthrough Therapy designation for PF614-MPAR, and expansion of intellectual property with a patent in Brazil. However, the significant decline in stock price due to financial losses and high cash burn could raise concerns about the company's stability. The initiation of a review of strategic alternatives also suggests the company is facing challenges.

The ownership structure of Ensysce Biosciences (ENSC) stock includes institutional, retail, and individual investors. Approximately 11.73% to 12.36% of the company's stock is owned by institutional investors, 0.62% is owned by insiders, and 87.64% is held by public companies and individual investors. Major institutional owners and shareholders include Adage Capital Partners Gp, L.l.c., DRW Securities, LLC, Perceptive Advisors Llc, Vanguard Group Inc, Hrt Financial Lp, Financial Plan, Inc., Geode Capital Management, Llc, Two Sigma Securities, Llc, Williams & Novak, LLC, Tru Independence Asset Management 2, Llc, Murchinson Ltd., Anson Funds Management LP, Citadel Advisors LLC, Virtu Financial LLC, and BlackRock, Inc. Joseph Edelman owns the most shares of Ensysce Biosciences.